The effectiveness of PSA testing was more marked at the Göteborg site of the ERSPC trial, with a risk reduction of 44% over 14 years in men aged 50-64 years.5 This effect size is larger than that observed for mammographic screening for breast cancer and faecal occult blood testing for colorectal cancer. This evidence concerns the gene KLK3 and breast carcinoma.